Want to see NIKI full AI Analyst Report?
Niki BioSolutions Inc (NIKI) AI Stock Analysis
Niki BioSolutions Inc
(NASDAQ:NIKI)
The score is constrained primarily by zero revenue, ongoing losses, persistent cash burn, and a pronounced technical downtrend. Improved leverage, narrowing losses, strategic merger synergies, and restored Nasdaq compliance provide meaningful but limited support.
Niki BioSolutions Inc (NIKI) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $144.14K
- Dividend Yield
- ―
- Average Volume (3M)
- 97.82K
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 1.71
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 1
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Niki BioSolutions Inc Business Overview & Revenue Model
Company Description
Niki BioSolutions is a biopharmaceutical company that resulted from the merger of Aptorum Group and DiamiR Biosciences. The company focuses on developing and commercializing a diverse portfolio of therapeutic and diagnostic assets. Its work spans fro...
Niki BioSolutions Inc Financial Statement Overview
Summary
Financial performance is weak overall: revenue remains at zero, profitability is negative, and cash burn continues. Narrowing losses, reduced cash-flow burn, and improved leverage provide partial offsets.
Income Statement
15Very NegativeBalance Sheet
45NeutralCash Flow
25Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 431.38K | 1.30M | 1.54M |
| Gross Profit | 0 | 0 | -255.00K | 10.57K | 80.06K | 81.85K |
| EBITDA | -825.13K | -1.82M | -3.71M | -9.22M | -9.97M | -25.83M |
| Net Income | -307.50K | -1.36M | -4.27M | -2.83M | -9.80M | -25.05M |
Balance Sheet | ||||||
| Total Assets | 18.69M | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M |
| Cash, Cash Equivalents and Short-Term Investments | 3.45M | 3.45M | 874.24K | 2.01M | 1.99M | 8.50M |
| Total Debt | 3.44M | 3.44M | 3.35M | 3.28M | 6.85M | 217.17K |
| Total Liabilities | 4.90M | 4.90M | 4.35M | 5.26M | 13.03M | 4.40M |
| Stockholders Equity | 23.16M | 23.16M | 21.13M | 24.85M | 15.71M | 23.61M |
Cash Flow | ||||||
| Free Cash Flow | -535.26K | -1.84M | -1.19M | -7.73M | -12.51M | -14.79M |
| Operating Cash Flow | -535.25K | -1.84M | -1.19M | -7.72M | -12.32M | -14.65M |
| Investing Cash Flow | 0 | 0 | 58.62K | 624.77K | 2.44M | 16.51M |
| Financing Cash Flow | 1.72M | 4.42M | 0 | 4.09M | 6.63M | 2.78M |
Niki BioSolutions Inc Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NIKI, the sentiment is Negative. The current price of 1.78 is below the 20-day moving average (MA) of 2.70, below the 50-day MA of 4.63, and below the 200-day MA of 7.71, indicating a bearish trend. The MACD of -0.87 indicates Negative momentum. The RSI at 21.06 is Positive, neither overbought nor oversold. The STOCH value of 25.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NIKI.
Niki BioSolutions Inc Risk Analysis
Niki BioSolutions Inc disclosed 73 risk factors in its most recent earnings report. Niki BioSolutions Inc reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
1 New RiskNiki BioSolutions Inc Peers Comparison
Overall Rating
- NIKI49Neutral
AEON48Neutral
IMNN46Neutral
DWTX45Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| NIKI | 49Neutral | $5.52M | -0.09 | -5.94% | ― | ― | ― |
| AEON | 48Neutral | $16.19M | -0.07 | 204.18% | ― | ― | 35.03% |
| IMNN | 46Neutral | $5.11M | -0.20 | -314.89% | ― | ― | 71.67% |
| DWTX | 45Neutral | $43.51M | -0.14 | -47.85% | ― | ― | 52.36% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| NIKI | Niki Biosolutions, Inc. | 1.77 | -12.33 | -87.45% | |
| IMNN | Imunon, Inc. | 0.91 | -2.94 | -76.39% | |
| DWTX | Dogwood Therapeutics Inc | 1.28 | -4.44 | -77.62% | |
| AEON | Aeon Biopharma, Inc. | 0.27 | -0.68 | -71.16% | |
| OSRH | Osr Holdings, Inc. | 0.15 | -0.45 | -75.08% |
Niki BioSolutions Inc Corporate Events
Niki BioSolutions Launches At-the-Market Stock Offering
NeutralOn October 9, 2026, Niki BioSolutions Inc entered into an at‑the‑market offering agreement with H.C. Wainwright & Co. and Brookline Capital Markets, allowing the company to sell up to $1.396 million of common stock from time to time....
Niki BioSolutions Highlights Strategic Synergies in Alzheimer’s Diagnostics
PositiveNiki BioSolutions Inc operates in the biotechnology and molecular diagnostics sector, focusing on non-invasive, blood-based tests for Alzheimer’s disease and broader brain health, alongside rare disease and neuro-oncology applications. Through...
Niki BioSolutions appoints new CEO and COO leadership
PositiveIn connection with a previously announced merger, Niki BioSolutions Inc. appointed Ian Huen as chief executive officer and Alidad Mireskandari as president and chief operating officer, with their agreements entered on September 1, 2026 and effective...
Niki BioSolutions Regains Nasdaq Bid-Price Compliance Status
PositiveOn March 5, 2026, Niki BioSolutions received a notice from Nasdaq that its common stock had closed below the $1.00 minimum bid price for 30 consecutive business days, triggering a compliance period through September 1, 2026. On August 4, 2026, Nasdaq...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 24, 2026